---
title: "ICOP says Consob suspends review clock on Trevi share-swap offer document"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295697166.md"
description: "ICOP launched a voluntary share-exchange offer for Trevi shares. CONSOB has suspended the review clock for up to 15 days after requesting additional detailed information. The review process will resume once ICOP completes and submits the required information package."
datetime: "2026-08-12T18:12:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295697166.md)
  - [en](https://longbridge.com/en/news/295697166.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295697166.md)
generator: "portal-rs"
---

# ICOP says Consob suspends review clock on Trevi share-swap offer document

-   ICOP launched a voluntary share-exchange offer for all ordinary shares of Trevi - Finanziaria Industriale listed on Euronext Milan. \* CONSOB requested additional detailed information, pausing review of the offer document for up to 15 calendar days. \* Review timing will restart once the information package is completed. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ICOP S.p.A. Socità Benefit published the original content used to generate this news brief via SDIR, the Italian regulatory disclosure system (Ref. ID: 1936-42-2026\_TELEBORSA.pdf), on August 12, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [TRVI.US](https://longbridge.com/en/quote/TRVI.US.md)
- [ICOP.US](https://longbridge.com/en/quote/ICOP.US.md)

## Related News & Research

- [Trevi Therapeutics to present Phase 2b CORAL nalbuphine ER quality-of-life data in IPF cough at ERS 2026](https://longbridge.com/en/news/297037112.md)
- [Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of "Buy" from Analysts](https://longbridge.com/en/news/296880224.md)
- [Agilyx (OB:AGLX) Stock Eyes GreenDot Strength As Earnings Quality Questions Linger](https://longbridge.com/en/news/297367001.md)
- [Veidekke (OB:VEI) Could Be 8% Undervalued Following NOK 212 Million Contract Win](https://longbridge.com/en/news/297396581.md)
- [How Zacks’ Strong Buy and Undervaluation Call Could Reshape Yara International’s (OB:YAR) Risk‑Reward Profile](https://longbridge.com/en/news/297426629.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**